Koenig Sheldon L. 4
4 · Esperion Therapeutics, Inc. · Filed Sep 20, 2022
Insider Transaction Report
Form 4
Koenig Sheldon L.
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2022-09-19$6.94/sh−3,394$23,548→ 198,257 total
Footnotes (2)
- [F1]Shares were sold to satisfy tax obligation on quarterly vested shares of restricted stock units.
- [F2]Consists of 198,257 shares of common stock held, including 2,880 shares acquired in Esperion's Employee Stock Purchase Plan on August 31, 2022.